ClinicalTrials.gg
CompletedNCT05026632Updated Oct 9, 2026

NPI-002 Intravitreal Implant for the Delay of Cataract Progression

A Phase 1/2 interventional study of NPI-002 Intravitreal Implant in Cataract, sponsored by Nacuity Pharmaceuticals, Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Nacuity Pharmaceuticals, Inc. · Phase 1/2, Interventional, and Prevention

How we know

Updated Oct 9, 2026Now CompletedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 17 studies in Cataract with a site in Australia — 2 open to participants now, 3 under way, none of them phase 3. Cataract · Australia.

Enrollment
11th of 14
24 · median 93
Started
2022
the only one that year
Phase 1/2
Only one
of the 17
Registered
11th of 17
by date
Lead sponsor
1 of 17
Nacuity Pharmaceuticals, Inc.

Among the 17 studies in Cataract with a site in Australia, this one is the 11th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2022, is the only one in phase 1/2, and was the 11th registered.

Cataract

1,633 studies on the registry are indexed under Cataract; 234 are open to participants now.

Browse Cataract studies →

Open to participants now

2 of the 17 studies in Cataract with a site in Australia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 143 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Cataract with a site in Australia, or all of them as a file.
02

Study summary

This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.

03

Conditions studied

  • Cataract

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Indicated for vitrectomy
  2. Natural Lens in place at time of vitrectomy
  3. Some cataract present as assessed pre-operatively

Exclusion criteria

Exclusion Criteria:

  1. Previous intraocular surgery in study eye.
  2. Clear zonular weakness or defects / coloboma.
  3. Not on stable dose of medications for other conditions.
  4. Need for oral during study participation.
  5. Evidence or history of uveitis, or ocular ischemia.
  6. Current smoker
  7. Use of supplemental oxygen
  8. Evidence or history of proliferative diabetic retinopathy.
  9. Current lung disease (PU, , Asthma) resulting in decreased oxygen saturation.
  10. Sensitivity to thiol compounds.
  11. Participation in another clinical trial.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Single NPI-002 Intravitreal Implant

    one NPI-002 implant inserted at the time of vitrectomy

    Drug: NPI-002 Intravitreal Implant

  • Experimental
    Double NPI-002 Intravitreal Implant

    two NPI-002 implants inserted at the time of vitrectomy

    Drug: NPI-002 Intravitreal Implant

  • No intervention
    Control

    No implant inserted at time of vitrectomy

Interventions

  • DrugNPI-002 Intravitreal Implant

    Implant inserted during vitrectomy.

06

What researchers measure

Primary outcomes

  1. Lens Densitometry

    Change from Baseline

    Time frame: 6 months

07

Study locations

1 site
  • Royal Adelaide Hospital
    Adelaide, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2022 to primary completion in Sep 2026, 55 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2021
First posted
Aug 30, 2021
StartActual
Jan 27, 2022
Primary completionActual
Sep 3, 2026
CompletionActual
Sep 3, 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 9, 2026
Enrollment
30 (estimated)→24 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Active, not recruiting→Completed
    Enrollment 30 (estimated)→24 (actual)
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05026632
Lead sponsor
Nacuity Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Aug 30, 2021
Start date
Jan 27, 2022
Primary completion
Sep 3, 2026
Completion
Sep 3, 2026
Last update
Oct 9, 2026

Study contacts

Jami R Kern, PhD
study director · Nacuity Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion